SYNkinase

Discover Premium Small Molecule Kinase Inhibitors at SYNkinase

SYNkinase is a leading producer of research-use-only biomedical reagents, serving life science and drug discovery researchers across universities, research institutes, and industries. Established in 2008, SYNkinase operates offices in Australia, the USA, and Europe, with research and development laboratories located in Shanghai, China. The company was founded by experts with over three decades of experience in pharmaceutical drug discovery, including specialists in kinase biology and medicinal and synthetic chemistry. The name ” SYNkinase ” is now an incorporated brand of AdipoGen Life Sciences.

Their Mission

SYNkinase is dedicated to providing life science researchers with access to the most comprehensive and up-to-date library of kinase inhibitors and other small molecule inhibitors targeting crucial therapeutic proteins for drug discovery. Their extensive library includes potent, pure, and research-relevant inhibitors specifically designed for protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK), and lipid kinases.

Cutting-Edge Compounds

Currently, there are over 150 kinase-targeted drugs in clinical trials or development. SYNkinase offers many of these compounds, including 24 FDA-approved small molecule inhibitors such as mTOR, BRaf, MEK, EGFR, JAK, VEGFR, and PI3K inhibitors. Additionally, they provide a wide range of inhibitors documented in scientific literature, including GPCR, TGF-β, MAP kinase, cell cycle, and epigenetic inhibitors.

Commitment to Quality

As a primary source manufacturer, SYNkinase is committed to maintaining the highest quality standards. They ensure consistent supply of high-quality materials and strive to be the first in the market with the most significant and innovative compounds. Their meticulous focus on quality guarantees that researchers receive reliable and cutting-edge products for their scientific endeavors.